PTGX(Protagonist Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $27.36M | $26.58M | $60.00M | $434.43M | $46.02M |
| 毛利润 | — | — | — | — | — |
| 营业利润 | −$125.84M | −$131.37M | −$93.65M | $252.84M | −$158.13M |
| 净利润 | −$125.55M | −$127.39M | −$78.95M | $275.19M | −$130.15M |
| 经营现金流 | −$107.86M | −$108.14M | −$70.24M | $184.15M | $57.67M |
| 自由现金流 | −$108.97M | −$108.93M | −$70.84M | $182.80M | $56.08M |
| 摊薄每股收益 | $-2.71 | $-2.60 | $-1.39 | $4.23 | $-2.05 |